Journal of cancer research and therapeutics
-
To assess whether the Helicobacter pylori (HP) infection can increase the risk of developing pancreatic cancer or not by meta-analysis. ⋯ Based on present open published data, HP infection can significantly increase the risk of developing pancreatic cancer. However, for small number of studies included in this meta-analysis and publication bias, more case-control or cohort studies are needed to further confirm this conclusion.
-
Meta Analysis
Cyclooxygenase-2 expression and association with skin cancer: A meta-analysis based on Chinese patients.
The purpose of this meta-analysis was to evaluate the association between cyclooxygenase-2 (Cox-2) expression and skin cancer. ⋯ According to the present published data, Cox-2 expression was closely correlated to skin cancer.
-
To assess the relationship between hepatitis B virus (HBV), hepatitis C virus (HCV), and HBV/HCV double infection and hepatocellular carcinoma risk in Chinese population. ⋯ For Chinese population, HBV, HCV or HBV/HCV double infection can significantly increase the risk of developing hepatocellular carcinoma.
-
X-ray cross-complementing groups 1 (XRCC1) rs1799782 C>T polymorphisms and colorectal cancer susceptibility were not clear. The purpose of this study was to evaluate the association between XRCC1 rs1799782 C>T polymorphisms and colorectal cancer susceptibility by meta-analysis. ⋯ Chinese Han people with rs1799782 TT/CT genotype of XRCC1 gene may have increased risk of developing colorectal.
-
Lung cancer continues to be a major health problem and the most common cancer-related mortality worldwide with about 80%-85% patients suffering from nonsmall cell lung cancer (NSCLC). More than 80% of NSCLC cases are often diagnosed as advanced stage and harbor epidermal growth factor receptor (EGFR) activating mutation. Although great success in initial response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) are found in EGFR-mutant NSCLC patients, acquired resistance usually occurs on the continuous treatment. ⋯ Increasing evidence has proven that non-coding RNA including long noncoding RNAs and microRNAs or new EGFR mutation is involved in acquired resistance. Preclinical and clinical Phase 1-3 evidence on combination drug therapy or new generation inhibitors with different tumor-targeting approaches have made those strategies the promising options for EGFR-TKI-resistant NSCLC therapy. This review aims to get deep insight into providing a state-of-the-art overview of the recent advances in the mechanisms of acquired resistance and new strategies for targeted cancer therapy in EGFR-TKI-resistant NSCLC.